Document is current
Any future updates will be listed below
-
Authors
Frara, Stefano https://orcid.org/0000-0002-1308-5598
Uygur, Meliha Melin https://orcid.org/0000-0002-6569-8142
Bolamperti, Filippo
di Filippo, Luigi
Doga, Mauro
Ferrari, Francesca
Losa, Marco https://orcid.org/0000-0001-7810-8247
Mortini, Pietro https://orcid.org/0000-0003-2320-2281
Giustina, Andrea https://orcid.org/0000-0001-6783-3398
-
Funding
Funding for this research was provided by:
BAP Research Project , Recep Tayyip Erdogan University, Turkey (1662)
Italian Minitry of University and Research (PRIN 2017S55RXB)
- License Information
-
More Information
Article History
Accepted: 22 April 2024
First Online: 27 May 2024
Declarations
:
: SF received research grant to Institution from Abiogen Pharma, consultancy, and speaker fees from Ipsen, Novartis and Pfizer, took part in advisory boards from Recordati and Novo Nordisk. AG received grants/scientific consultancy from Abiogen, Chiasma, Ipsen, Pfizer, Recordati and research grants to Institution from Abiogen, Ipsen, Novartis, Pfizer, and Takeda. The other Authors declare that they have no conflicts of interests.
